SML Genetree has entered into a partnership with ResInnova Clinical Diagnostics, a CLIA-certified laboratory in the United States, to expand the supply of molecular diagnostic products and strengthen local collaboration in the U.S. market.
The partnership marks an important milestone in SML Genetree's expansion into the U.S. molecular diagnostics market, particularly in the rapidly growing Laboratory Developed Test (LDT) sector. Since initiating exports to the United States in May 2026, the company has successfully completed product performance evaluations in collaboration with ResInnova Clinical Diagnostics. Building on these results, SML Genetree plans to accelerate the commercialization and marketing of its NamuPlex™ product portfolio while expanding strategic partnerships throughout the United States.
On July 30, Dongsoo Lee, Chief Executive Officer of SML Genetree, visited ResInnova Clinical Diagnostics to commemorate the collaboration by presenting a partnership certificate. The agreement reflects both organizations' commitment to establishing a CLIA laboratory-based collaboration framework, introducing SML Genetree's NamuPlex™ molecular diagnostics portfolio to the U.S. market, and identifying additional opportunities for local cooperation.
ResInnova Clinical Diagnostics is a U.S.-based clinical laboratory that provides diagnostic testing services under Clinical Laboratory Improvement Amendments (CLIA) certification. CLIA-certified laboratories play a critical role in the validation, implementation, and operation of diagnostic testing services, including Laboratory Developed Tests (LDTs), ensuring compliance with U.S. regulatory and quality standards.
SML Genetree has developed and commercialized a broad portfolio of real-time PCR-based molecular diagnostic assays covering infectious diseases, including sexually transmitted infections, urinary tract infections, respiratory infections, and gastrointestinal infections. Through its proprietary NamuPlex™ brand, the company continues to expand its multiplex molecular diagnostics portfolio while developing products and collaboration models tailored to the needs of the U.S. market.
"Our partnership with ResInnova Clinical Diagnostics represents a significant step toward establishing a practical CLIA laboratory-based collaboration framework in the United States," said Dongsoo Lee, Chief Executive Officer of SML Genetree. "The U.S. is one of the world's most important markets for molecular diagnostics and Laboratory Developed Tests. Through close collaboration with trusted local partners, we will continue to strengthen the credibility of our products and expand access to innovative molecular diagnostic solutions."
SML Genetree officially entered the U.S. market with its first product exports in May 2026. Through this partnership with ResInnova Clinical Diagnostics, the company intends to further expand its U.S. collaboration network and reinforce its position as a global leader in molecular diagnostics.
Source: Newswire | 2026.08.04
https://www.newswire.co.kr/newsRead.php?no=1039832
SML Genetree has entered into a partnership with ResInnova Clinical Diagnostics, a CLIA-certified laboratory in the United States, to expand the supply of molecular diagnostic products and strengthen local collaboration in the U.S. market.
The partnership marks an important milestone in SML Genetree's expansion into the U.S. molecular diagnostics market, particularly in the rapidly growing Laboratory Developed Test (LDT) sector. Since initiating exports to the United States in May 2026, the company has successfully completed product performance evaluations in collaboration with ResInnova Clinical Diagnostics. Building on these results, SML Genetree plans to accelerate the commercialization and marketing of its NamuPlex™ product portfolio while expanding strategic partnerships throughout the United States.
On July 30, Dongsoo Lee, Chief Executive Officer of SML Genetree, visited ResInnova Clinical Diagnostics to commemorate the collaboration by presenting a partnership certificate. The agreement reflects both organizations' commitment to establishing a CLIA laboratory-based collaboration framework, introducing SML Genetree's NamuPlex™ molecular diagnostics portfolio to the U.S. market, and identifying additional opportunities for local cooperation.
ResInnova Clinical Diagnostics is a U.S.-based clinical laboratory that provides diagnostic testing services under Clinical Laboratory Improvement Amendments (CLIA) certification. CLIA-certified laboratories play a critical role in the validation, implementation, and operation of diagnostic testing services, including Laboratory Developed Tests (LDTs), ensuring compliance with U.S. regulatory and quality standards.
SML Genetree has developed and commercialized a broad portfolio of real-time PCR-based molecular diagnostic assays covering infectious diseases, including sexually transmitted infections, urinary tract infections, respiratory infections, and gastrointestinal infections. Through its proprietary NamuPlex™ brand, the company continues to expand its multiplex molecular diagnostics portfolio while developing products and collaboration models tailored to the needs of the U.S. market.
"Our partnership with ResInnova Clinical Diagnostics represents a significant step toward establishing a practical CLIA laboratory-based collaboration framework in the United States," said Dongsoo Lee, Chief Executive Officer of SML Genetree. "The U.S. is one of the world's most important markets for molecular diagnostics and Laboratory Developed Tests. Through close collaboration with trusted local partners, we will continue to strengthen the credibility of our products and expand access to innovative molecular diagnostic solutions."
SML Genetree officially entered the U.S. market with its first product exports in May 2026. Through this partnership with ResInnova Clinical Diagnostics, the company intends to further expand its U.S. collaboration network and reinforce its position as a global leader in molecular diagnostics.
Source: Newswire | 2026.08.04
https://www.newswire.co.kr/newsRead.php?no=1039832